Late onset and persistent parosmia and dysgeusia as neurosensorial complication by the SARS virus COV 2

Patricia Sequeira Rodriguez, Rafael Santana Ortiz,at. al.Otolaryngol 2023: 2023.  doi:  10.1016/j.xocr.2023.100510, PMCID: PMC9850639,PMID: 3669145 Abstract About the neurological manifestations of COVID-19, smell impairment with some distortion or parosmia is currently one of the…[...]

Read More

Breathing difficulties after covid-19: a guide for primary care

BMJ 2023; 381 doi: https://doi.org/10.1136/bmj-2023-074937 (Published 14 June 2023)Cite this as: BMJ 2023;381:e07493, Rachael Evans What you need to know Breathing difficulties are common sequelae of covid-19 Typically there are multiple contributing factors to breathing difficulties within…[...]

Read More

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants

Lorenza Bellusci, Hana Golding, and Surender Khurana Journal of Clinical Investigation Published 2023 - More infoView PDF  Convalescent plasma (CP) and hyperimmune intravenous immunoglobulins (IVIGs) are routinely used to treat patients with COVID-19.…[...]

Read More

Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders

Hironori Tsuchiya, Christos Rahiotis, Academic Editor and Nikolaos Gkantidis, Academic EditorDent J (Basel). 2023 Jun; 11(6): 140. Published online 2023 May 25. doi: 10.3390/dj11060140, PMCID: PMC10297082 PMID: 37366663 Abstract Since the worldwide spread of severe acute respiratory syndrome…[...]

Read More

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, Hassan Hartman, Alessandra Løchen, Thomas P. Peacock & Christopher Ruis Nature (2023) Cite this article Abstract Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing…[...]

Read More